Absci is trading 5.6% up at $9.80, rebounding from its August 20 close of $9.28 after a volatile week, though no immediate reason has been identified.
- No new company-specific announcement or reliable catalyst was identified for August 21, 2026.
- The latest material update came August 11, involving positive interim ABS-201 data and a $100 million financing with Eli Lilly.
- Broader biotech sentiment is currently negative.